Form 4: ADMA Biologics Director Steve Elms Reports Acquisition of Restricted Stock Units and Stock Options

Director Steve Elms reports acquisition of restricted stock units and stock options in ADMA Biologics, along with details of beneficial ownership.

Summary

• On February 19, 2025, Steve Elms, a director of ADMA Biologics, reported the acquisition of 10,889 restricted stock units (RSUs) and 16,279 stock options.
• The RSUs vest in two equal installments over a year, while the stock options vest monthly over a year, both contingent on continued service.
• Elms also reported beneficial ownership of 87,330 shares of common stock and indirect ownership of 2,124,671 shares through Aisling Capital II LP.
• The stock options have an exercise price of $16.07 and expire on February 19, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects insider confidence through equity ownership and option grants. It's a routine filing, but insider activity is generally viewed favorably.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedules of the RSUs and stock options are contingent on the Reporting Person's continued service, suggesting an expectation of continued involvement with the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of shares and options by a director can positively influence shareholder sentiment.

Key Dates

Keywords

ADMA Biologics, Steve Elms, Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, Director, Aisling Capital